dIscOverNET Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors.
- Coordinator
- Universiteit Antwerpen, Belgium
- Runs
- 1 January 2027 to 31 December 2030
- Status
- Running
- EU funding
- €4.6m
- Total cost
- —
- Partners
- 23 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311447
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite significant investments of resources, policies, global partnerships and social and financial efforts in the fight against cancer, we are currently still unable to achieve long-term disease control for patients with neuroendocrine tumors (NET). Moreover, despite the emphasis of both Europe’s Beating Cancer Plan and the European Initiative on Rare Cancers on advancing research and innovation in rare tumors, only limited progress has been made in the field of NET over the last decade.
Particularly, the transformative waves of immunotherapy success across oncology have not yet reached NET. By bringing together experts in NET biology, pioneers in immuno-oncology research, clinicians from NET expert centers, patient advocates, and representatives of the public health sector, dIscOverNET will lead to outstanding interdisciplinary and intersectoral research. This dynamic and synergistic collaboration, will explore the potential of leveraging the immune system for the treatment of NETs, which might be able to induce durable anti-tumor responses and cure NETs.
Through a comprehensive, multidisciplinary training program aligned with European doctoral training principles, the dIscOverNET doctoral candidates will be equipped to take on leading roles in European industry, academia, or government.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Antwerpen | Antwerpen | Belgium | Coordinator |
| Immunewatch BV | Antwerpen | Belgium | Associatedpartner |
| Sciensano | Elsene | Belgium | Associatedpartner |
| SGS Belgium N.V. | Antwerpen | Belgium | Associatedpartner |
| Universitair Ziekenhuis Antwerpen | Edegem | Belgium | Associatedpartner |
| myNeo | Gent | Belgium | Participant |
| European Molecular Biology Laboratory | Heidelberg | Germany | Participant |
| European Neuroendocrine Tumor Society e. V. (ENETS) | Berlin | Germany | Associatedpartner |
| Fundacio Institut D'investigacio Biomedica De Bellvitge | L'Hospitalet De Llobregat | Spain | Associatedpartner |
| Universidad De Cordoba | Cordoba | Spain | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Orano Ds - Demantelement Et Service | Massy | France | Associatedpartner |
| Universite Lyon 1 Claude Bernard | Villeurbanne Cedex | France | Participant |
| Universite Paris Cite | Paris | France | Associatedpartner |
| Universita Degli Studi Di Bari Aldo Moro | Bari | Italy | Participant |
| Crown Bioscience Netherlands BV | Leiden | Netherlands | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Erasmus Universiteit Rotterdam | Rotterdam | Netherlands | Associatedpartner |
| Google Cloud Technology Solutions Netherlands BV | Utrecht | Netherlands | Associatedpartner |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Participant |
| University of London | London | United Kingdom | Associatedpartner |
| International Neuroendocrine Cancer Alliance Inc. | Newton, Boston | United States | Associatedpartner |
| Oncoassign Corporation | New Castle | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI